Twist Bioscience Corp
Twist Bioscience Corp is a U.S.-based synthetic biology company that manufactures synthetic DNA and related life-science products using a proprietary silicon-based DNA writing platform. Its offerings support customers in healthcare, academic research, food and agriculture, and industrial applications, with sales made through direct channels, distributors, and an e-commerce platform.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProducts and workflows used in next-generation sequencing and DNA reading applications.
Custom DNA sequences manufactured for research, discovery, and engineering biology.
Massively parallel oligonucleotide libraries used in screening and research workflows.
Biopharma services for antibody discovery, optimization, and development.
Prepared DNA libraries used in sequencing, screening, and research applications.
Products
Reported · share of revenue- Ngs Tools55.3 %
- Synthetic Genes30.2 %
- Antibody Discovery6.2 %
- Oligo Pools5.4 %
- Dna and Biopharma Libraries3.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Twist sells to a broad base of more than 3,800 customers across healthcare, academic research, industrial, and food/agriculture end markets. Buyers include biopharma and biotech teams, research institutions, and industrial R&D groups that need custom DNA, sequencing tools, or discovery services to accelerate experiments and product development.
Buys synthetic DNA, antibody discovery, and protein-related services for therapeutic research and development.
Buys custom DNA, libraries, and sequencing tools for discovery, validation, and education.
Buys DNA-based products to support engineering of specialty chemicals and materials.
Buys synthetic biology tools for crop improvement and agricultural R&D.
Buys NGS tools and applications for sequencing workflows and sample preparation.
Strategy
Twist’s strategy centers on scaling its silicon-based DNA synthesis platform across more product lines and end markets. It also emphasizes a multi-channel commercial model, combining direct sales, e-commerce, and regional consultants to reach a large and fragmented customer base.
A wider product set increases customer wallet share and cross-selling across research workflows.
The customer base is broad and fragmented, so efficient ordering and support improve reach and retention.
These end markets can use multiple Twist products and services across discovery workflows.
Geography
Q2/2026Twist sells globally, with revenues reported across the Americas, EMEA, and APAC. The Americas are the largest region, while EMEA is a meaningful second market and APAC contributes a smaller but important share of demand; the company also uses commercial consultants in Europe and Asia to support local selling.
Share of the revenue the company reports by geography.
Risks
Twist depends heavily on proprietary DNA synthesis technology, so intellectual property protection, biosecurity compliance, and product misuse are central risks. It also faces customer concentration, competitive pressure, and execution risk as it tries to grow across multiple end markets and geographies.
- Intellectual property protectionImpact: HighLikelihood: Medium
The business depends on proprietary synthesis methods and software that competitors could attempt to copy or design around.
Exposure: Core platform and manufacturing process
- Biosecurity and regulatory complianceImpact: HighLikelihood: Medium
DNA synthesis is subject to biosafety and biosecurity rules that can limit what sequences can be produced and how orders are screened.
Exposure: Manufacturing and order screening
- Customer concentration and retentionImpact: MediumLikelihood: Medium
Revenue can be affected if a limited number of large customers reduce orders or switch suppliers.
Exposure: Synthetic DNA and NGS customer base
- Competitive pressureImpact: MediumLikelihood: Medium
The company operates in a technically demanding market where rivals can compete on price, speed, and service.
Exposure: Synthetic biology and sequencing workflows
- Reputational risk from product useImpact: MediumLikelihood: Low
Customers may use DNA products in ways that attract scrutiny or damage trust in the platform.
Exposure: Global sales and distribution
Accounting
Judgemental itemsDifferent product and service lines may recognize revenue at different points in time, affecting quarterly comparability.
Impact: Reported revenue mix and timing
Manufacturing and technology assets may require impairment testing if utilization or expected cash flows change.
Impact: Operating results and asset carrying values
The sale of the DNA digital data storage business created a non-operating gain that can distort underlying performance.
Impact: Net income and comparability
Management must estimate asset values, reserves, and other balances that are not directly observable.
Impact: Balance sheet and earnings volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
BioScience Health Innovations, Inc.
BHIC · Services-Computer Processing & Data Preparation
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Last updated: 24/09/2026